[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

310-794-7274

Email address

mrichley@mednet.ucla.edu

Condition

Diabetes Mellitus, Type 2,Gestational Diabetes

Treatment type

Interventional

Investigational product

Insulin Detemir

Phase

Phase 2

Sponsor

University of California, Los Angeles

ClinicalTrials.gov identifier

NCT05124457

Study number

DETERMINE

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

The purpose of the study is to compare rates of neonatal hypoglycemia with maternal NPH vs determir use.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

  1. Inclusion criteria will include pregnant women with pre-existing T2DM and GDM who requiring insulin to manage their blood sugars in pregnancy.
Exclusion criteria

  1. Multiple Gestation
  2. Type 1 Diabetes mellatus
  3. Age < 18
  4. Known or suspected hypersensitivity to NPH or insulin detemir
  5. Known fetal major malformations
  6. Chronic renal or hepatic insufficiency
  7. Known to be HIV, Hepatitis B, or Hepatitis C positive
  8. Indication for planned premature delivery (placenta accrete, or prior classical cesarean delivery)
  9. Insulin dependent before conception

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site